Insider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells 4,106 Shares of Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The stock was sold at an average price of $8.40, for a total transaction of $17,732.40.

MiMedx Group Trading Up 0.4 %

Shares of NASDAQ:MDXG opened at $7.92 on Friday. The firm has a fifty day moving average of $8.45 and a two-hundred day moving average of $7.81. The firm has a market capitalization of $1.17 billion, a P/E ratio of 14.40 and a beta of 1.97. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. On average, equities analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Phocas Financial Corp. bought a new position in shares of MiMedx Group during the 4th quarter valued at $2,016,000. Paradigm Capital Management Inc. NY raised its holdings in shares of MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company’s stock valued at $45,082,000 after purchasing an additional 22,131 shares in the last quarter. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group during the 4th quarter valued at $35,000. Virtus Investment Advisers Inc. bought a new position in shares of MiMedx Group during the 4th quarter valued at $335,000. Finally, State of Wyoming raised its holdings in shares of MiMedx Group by 16.3% during the 4th quarter. State of Wyoming now owns 201,111 shares of the company’s stock valued at $1,935,000 after purchasing an additional 28,230 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.